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alternative donors has been associated with increased graft
failure, graft versus host disease (GVHD), and transplant-
related mortality (TRM). HSCT using alternative donors with
post-transplantation cyclophosphamide (PT/Cy) has been
performed for hematologic malignancies with engraftment,
GVHD, and TRM comparable to that seen with HLA-matched
related donors. There are limited reports of HSCT in non-
malignant disorders using alternative donors and PT/Cy.
Design: We transplanted 9 patients with non-malignant
conditions (CGD¼3, DKC¼2, DBA¼1, HyperIgM¼1, XIAP¼1,
IPEX¼1) using an alemtuzamab/ﬂudarabine based reduced
intensity conditioning (RIC). All patients received GVHD
prophylaxis with PT/Cy, with the addition of mycophenolate
mofetil and tacrolimus for HSCT with haploidentical donors
and for alkylator-sensitive diagnoses (DKC). Six patients had
10/10 HLA-matched unrelated donors, and 3 had HLA-hap-
loidentical related donors.
Results: All 9 patients successfully engrafted by day 30. Ul-
timately, all patients have had sustained donor engraftment
sufﬁcient to eliminate manifestations of their underlying
diseases. 6 of 9 patients are full donor chimeras off immu-
nosuppression,1 patient is a stablemixed donor chimera (76%
CD3+ T cells) off immunosuppression, 1 patient is a stable
mixed donor chimera on a calcineurin inhibitor (CNI), and 1
patient had secondary graft failure but was ultimately
retransplanted with myeloablative conditioning using the
same donor, resulting in full donor chimerism and elimina-
tion of disease. One patient developed Grade 1 and one pa-
tient Grade 2 acute GVHD, both treated successfully with
steroids and a CNI. Mild skin chronic GVHD developed in 1
patient, treated successfully with phototherapy. No serious
infections occurred and there was no TRM. 1 patient devel-
oped veno-occlusive disease, treated successfully with
deﬁbrotide. Disease-free survival is 89% with a median
follow-up of 14 months (6-30 months). The patient with
secondary graft failure is now disease-free after myeloa-
blative transplant, for an overall disease-free survival of 100%
at a median of 14 months follow-up (6-60 months). Overall
survival is 100%.
Conclusion: We have observed successful engraftment suf-
ﬁcient to eliminate manifestations of disease, limited GVHD,
and no TRM in 9 patients with nonmalignant disorders using
alternative donors, RIC, and PT/Cy. RIC HSCT with PT/Cy
shows promise for curing nonmalignant pediatric disorders,
and potentially eliminates the need for CNI use after MUD
BMT. Development of prospective clinical trials to conﬁrm
these observations is warranted.100
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Autologoushematopoietic stemcell transplantation (HSCT)of
gene-modiﬁed cells (gene therapy) has shown clinical beneﬁt
for ADA-SCID when combined with non-myeloablative con-
ditioning and enzyme replacement therapy (ERT) cessation.
In a Phase II study (2009-2012) closed to enrollment
(NCT00794508), patients received autologous CD34+ cells
modiﬁed with the MND-ADA g-retroviral vector after condi-
tioning with busulfan (4 mg/kg) and ERT cessation (n¼10).
Patients were treated between 3 months and 15 years of age
(median¼11.5 months) and follow-up ranges from 22-64
months. With the exception of the oldest patient (at 15y), all
others remain off ERTwith normalized PBMCADA activity. All
nine remaining off ERT show normal proliferative responses
to mitogens and three of nine were able to discontinue IVIg.
MND-ADA is detected in PBMC (0.1-2.6 VCN) and in gran-
ulocytes (0.01-0.3 VCN) at most recent visit. A new Phase I/II
trial was opened in May 2013 (NCT01852071) in which sub-
jects have received autologous CD34+ cells modiﬁed with a
self-inactivating lentiviral vector (EFS-ADA) after condition-
ing with busulfan (4 mg/kg) with ERT cessation at 30 days
post-transplant (n¼6). Eight subjects have been enrolled at 4-
42monthsoldand the sixwhoarepast30days remainoff ERT.
The patients with the longest follow-up have normal or
higher PBMC ADA activity and good immune reconstitution.
Monitoring for insertional oncogenesis is on-going in both
studies and has not detected any monoclonal proliferative
events. These results demonstrate the efﬁcacy and safety of
autologous transplant/gene therapy for ADA SCID.101
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Background: In children, the therapeutic drug monitoring
(TDM) of intravenous (IV) busulfan (BU) in alloHCT can
